Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-622-4003
Debt
Current Ratio11.78
Quick Ratio11.78
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Price / Book1.60
Profitability
Net Income$-52,020,000.00
Net MarginsN/A
Return on Assets-58.44%
Miscellaneous
Employees35
OptionableOptionable
Zafgen (NASDAQ:ZFGN) Frequently Asked Questions
What is Zafgen's stock symbol?
Zafgen trades on the NASDAQ under the ticker symbol "ZFGN."
How were Zafgen's earnings last quarter?
Zafgen Inc (NASDAQ:ZFGN) posted its quarterly earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.04. View Zafgen's Earnings History.
When is Zafgen's next earnings date?
What price target have analysts set for ZFGN?
4 Wall Street analysts have issued twelve-month price objectives for Zafgen's stock. Their forecasts range from $14.00 to $20.00. On average, they expect Zafgen's share price to reach $17.3333 in the next twelve months. This suggests a possible upside of 279.9% from the stock's current price. View Analyst Price Targets for Zafgen.
What is the consensus analysts' recommendation for Zafgen?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zafgen in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zafgen.
Has Zafgen been receiving favorable news coverage?
Media stories about ZFGN stock have been trending positive on Thursday, according to InfoTrie. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Zafgen earned a media sentiment score of 2.6 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an impact on the company's share price in the next several days.
Are investors shorting Zafgen?
Zafgen saw a decline in short interest in December. As of December 14th, there was short interest totalling 498,180 shares, a decline of 31.3% from the November 30th total of 725,401 shares. Based on an average daily trading volume, of 303,569 shares, the short-interest ratio is currently 1.6 days. Currently, 1.5% of the company's stock are short sold. View Zafgen's Current Options Chain.
Who are some of Zafgen's key competitors?
Some companies that are related to Zafgen include Rocket Pharmaceuticals (RCKT), Urogen Pharma (URGN), Omeros (OMER), Dicerna Pharmaceuticals (DRNA), Aurinia Pharmaceuticals (AUPH), Vectura Group (VEGPF), Kura Oncology (KURA), Ra Pharmaceuticals (RARX), CannTrust (CNTTF), ANI Pharmaceuticals (ANIP), Eagle Pharmaceuticals (EGRX), Basilea Pharmaceutica (BPMUF), ChemoCentryx (CCXI), Viking Therapeutics (VKTX) and Karyopharm Therapeutics (KPTI).
Who are Zafgen's key executives?
Zafgen's management team includes the folowing people:
- Mr. Jeffrey S. Hatfield, CEO & Director (Age 61)
- Dr. Thomas E. Hughes, Pres & Chief Scientific Officer (Age 59)
- Ms. Patricia L. Allen, Chief Financial Officer (Age 57)
- Dr. Dennis D. Kim M.D., MBA, Chief Medical Officer (Age 49)
- Dr. James E. Vath, Head of Discovery & Devel. (Age 58)
Who are Zafgen's major shareholders?
Zafgen's stock is owned by many different of retail and institutional investors. Top institutional investors include Meeder Asset Management Inc. (0.02%). Company insiders that own Zafgen stock include Dennis D Kim, Frances K Heller and Thomas E Hughes. View Institutional Ownership Trends for Zafgen.
Which major investors are buying Zafgen stock?
ZFGN stock was purchased by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc.. Company insiders that have bought Zafgen stock in the last two years include Dennis D Kim and Frances K Heller. View Insider Buying and Selling for Zafgen.
How do I buy shares of Zafgen?
Shares of ZFGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zafgen's stock price today?
One share of ZFGN stock can currently be purchased for approximately $4.5631.
How big of a company is Zafgen?
Zafgen has a market capitalization of $176.24 million. The biopharmaceutical company earns $-52,020,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis. Zafgen employs 35 workers across the globe.
What is Zafgen's official website?
How can I contact Zafgen?
Zafgen's mailing address is 175 PORTLAND STREET 4TH FLOOR, BOSTON MA, 02114. The biopharmaceutical company can be reached via phone at 617-622-4003 or via email at [email protected]
MarketBeat Community Rating for Zafgen (NASDAQ ZFGN)
MarketBeat's community ratings are surveys of what our community members think about Zafgen and other stocks. Vote "Outperform" if you believe ZFGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZFGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
